Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster.BURLINGTON, Mass., May 13, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced a strategic partnership between GENEWIZ from Azenta Life Sciences, a global provider of multiomics and synthetic solutions services, and Form Bio, a leading artificial intelligence (AI) life sciences technology company, to enhance adeno-associated virus (AAV) gene therapy developme ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to _________ Commission File Number 000-25434 AZENTA, INC. (Exact name of registrant as specified in its charter) Delaware 04-30 ...

Azenta (AZTA) Q2 2025 Earnings Call May 07, 2025 08:30 AM ET Company Participants Yvonne Perron - VP - Financial Planning & Analysis and Investor RelationsJohn Marotta - President & CEOLawrence Lin - Executive VP & CFOVijay Kumar - Senior Managing DirectorPaul Knight - Managing Director Conference Call Participants David Saxon - Senior AnalystMatthew Stanton - AnalystBrendan Smith - Director & Senior Analyst Operator Greetings and welcome to the Azenta Q2 twenty twenty five Financial Results. During the pre ...

Azenta (AZTA) Q2 2025 Earnings Call May 07, 2025 08:30 AM ET Company Participants Yvonne Perron - VP - Financial Planning & Analysis and Investor RelationsJohn Marotta - President & CEOLawrence Lin - Executive VP & CFOVijay Kumar - Senior Managing DirectorPaul Knight - Managing Director Conference Call Participants David Saxon - Senior AnalystMatthew Stanton - AnalystBrendan Smith - Director & Senior Analyst Operator Greetings and welcome to the Azenta Q2 twenty twenty five Financial Results. During the pre ...

Azenta (AZTA) Q2 2025 Earnings Call May 07, 2025 08:30 AM ET Speaker0 Greetings and welcome to the Azenta Q2 twenty twenty five Financial Results. During the presentation, all participants will be in a listen only mode. Afterwards, we will conduct a question and answer session. As a reminder, this conference is being recorded Wednesday, 05/07/2025. I will now turn the conference over to Yvonne Perron, Vice President, FP and A and Investor Relations. Speaker1 Thank you, operator, and good morning to everyone ...

© 2025 Azenta, Inc. • All rights reserved 1 Conference Call Fiscal Second Quarter 2025 Financial Results May 7, 2025 1 Safe Harbor Statement "Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Company performance, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to materially differ, either better or worse, from those projected. ...

Azenta Reports Second Quarter Results for Fiscal 2025, Ended March 31, 2025 BURLINGTON, Mass., May 7, 2025 (PR Newswire) – Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the second quarter ended March 31, 2025. The results of B Medical Systems are treated as discontinued operations and reflected in total diluted EPS, following the Company's announcement in the first fiscal quarter of 2025 of its intention to pursue a sale. | | | | | | | Quarter Ended | | | | --- | --- | --- | --- | --- | - ...

Core Insights - The company reported a total revenue of $143 million for the quarter ended March 31, 2025, reflecting a 5% increase year-over-year, driven by growth in Sample Management Solutions and Multiomics [2][7] - The diluted EPS from continuing operations was $(0.40), compared to $(0.29) in the same quarter of the previous year, indicating a significant loss [2][24] - The company has a strong cash position with total cash, cash equivalents, and marketable securities amounting to $540 million as of March 31, 2025 [14] Financial Performance - Revenue from continuing operations was $143 million, down 3% from the previous quarter but up 5% year-over-year [2][7] - Organic revenue growth was 6% year-over-year, with Sample Management Solutions revenue at $80 million, up 8% year-over-year [2][7] - Adjusted EBITDA for continuing operations was $14 million, with an adjusted EBITDA margin of 10.0%, an improvement of 400 basis points year-over-year [2][7] Management Commentary - The CEO highlighted the company's strong performance amidst a challenging macroeconomic environment, emphasizing the resilience of the portfolio and the commitment of the teams [3] - The management expressed confidence in the company's positioning and disciplined operations while navigating uncertainties [3] Cash Flow and Guidance - Operating cash flow for the quarter was $14 million, with capital expenditures of $7 million, resulting in free cash flow of $7 million [14] - The company reiterated its revenue guidance for fiscal year 2025, expecting total organic revenue growth in the range of 3% to 5% compared to fiscal 2024 [14]

Company Overview - Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions globally, facilitating faster market access for impactful breakthroughs and therapies [3] - The company offers a comprehensive range of reliable cold-chain sample management solutions and multiomics services, focusing on drug development, clinical research, and advanced cell therapies [3] - Azenta operates under several industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey [3] Financial Announcement - Azenta will announce its fiscal second quarter 2025 earnings on May 7, 2025, before the market opens, covering the period that ended on March 31, 2025 [1] - A conference call and live webcast to discuss the financial results will take place on the same day at 8:30 a.m. Eastern Time, accessible via the Azenta website [2] - A replay of the conference call will be available starting at 8:30 a.m. ET on May 8, 2025 [2] Operational Footprint - Azenta is headquartered in Burlington, Massachusetts, with operational presence in North America, Europe, and Asia [4]

Core Insights - Azenta, Inc. published its annual Environmental, Social, & Governance (ESG) report, emphasizing its commitment to ESG priorities and showcasing accomplishments for the fiscal year ending September 30, 2024 [1][2] ESG Achievements - The company achieved a ~20% reduction in Scope 1 & 2 Greenhouse Gas emissions (market-based) compared to 2022, while sourcing over 60% of its electricity from renewable sources [6] - Launched the BioArc™ Ultra product for large-scale, eco-friendly sample storage, advancing sustainable innovation [6] - Established the Azenta PRISM LGBTQIA+ Employee Resource Group (ERG) to promote inclusivity and support for a diverse workforce [6] - Rolled out the Azenta THRIVE platform to enhance employee well-being and engagement, providing access to professional training through LinkedIn Learning® [6] - Strengthened sustainable procurement efforts by training 100% of the global buyer team on sustainable sourcing and evaluating the ESG performance of over half of its Tier 1 suppliers by spend in partnership with EcoVadis® [6] Company Overview - Azenta, Inc. is a leading provider of life sciences solutions, facilitating faster market access for breakthroughs and therapies [3] - The company offers a comprehensive suite of cold-chain sample management solutions and multiomics services for pharmaceutical, biotech, academic, and healthcare institutions globally [3] - Azenta is headquartered in Burlington, MA, with operations across North America, Europe, and Asia [4]